🇺🇸 FDA
Pipeline program

EFAVIRENZ

HUB-NEU-2023-01

Phase 2 small_molecule active

Quick answer

EFAVIRENZ for Type C Niemann-Pick Disease is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Type C Niemann-Pick Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials